Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment

Improvements in surgery and radiotherapy techniques have led to only a mode st increase in the 5-year survival rate for patients with head and neck can cer. This is because the pattern of clinical disease Is changing, such that locoregional recurrence now accounts for fewer treatment failures, but mor e patients develop a second primary cancer or distant metastatic disease, I n this study, we have used the p53 phage plaque assay, immunocytochemistry, and mutational analysis to assess the contribution of minimal residual can cer and genetic aberrations in clinically normal upper aerodigestive tract mucosa to treatment failure. Eighteen consecutive patients with oral tumors , with conventional clear margins, have been followed for a minimum of 36 m onths, Molecular assessment identified tumor-positive surgical margins for 6 of 11 assessable patients and additional tumor-positive lymph nodes for t hree cases. Disseminated malignant cells were detected in the hematopoietic cell compartment for six cases, and one patient had molecular evidence of field cancerization, Locoregional recurrence developed in five patients wit h tumors harboring a p53 gene mutation; four of these were associated with tumor-positive surgical margins, and one was associated with molecular evid ence of field cancerization. Radiotherapy to the primary site did not preve nt development of local recurrence when the residual tumor harbored ap53 ge ne mutation, Three of six cases with a tumor-positive bone marrow aspirate developed distant metastases, These findings reveal that molecular and immu nocytochemical detection of minimal residual cancer and field cancerization can help identify patients who may develop locoregional or distant recurre nce and justify further studies to evaluate the contribution of these remai ning malignant cells to treatment failure.